ClinicalTrials.gg
RecruitingNCT06085937Updated Apr 15, 2026

Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department

A Phase 1 interventional study of Ketamine in Suicide, Suicidal Ideation and Depression, sponsored by Lindsay Maguire, MD. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Primary conditionSuicidal IdeationRegistry: SuicideReclassifiedWhy we changed it
Registry
Suicide — the first condition term the registry derived for this study.
ClinicalTrials.gg
Suicidal Ideation
Why
  1. Suicide is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Suicidal Ideation, a narrower term within Suicide.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Lindsay Maguire, MD · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing ketamine in Suicidal Ideation — 8 open to participants now, 9 under way, 3 of them phase 3. Ketamine · Suicidal Ideation.

Planned enrollment
12th of 36
50 · median 22
Started
2024
with 2 others
Phase 1
5 of 36
1 open now
Registered
30th of 36
by date

Among the 36 studies testing ketamine in Suicidal Ideation, this one is the 12th largest by planned enrollment, is one of 3 that started in 2024, is one of 5 in phase 1, and was the 30th registered.

Suicidal Ideation

570 studies on the registry are indexed under Suicidal Ideation; 204 are open to participants now.

Browse Suicidal Ideation studies →

Open to participants now

8 of the 36 studies testing ketamine in Suicidal Ideation are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 135 Suicidal Ideation studies recruiting now, 52 (39%) set no upper age limit and 79 (59%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing ketamine in Suicidal Ideation, or all of them as a file.
02

Study summary

There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.

Read the detailed description

In this phase one trial, the investigators' objective is to establish the safety and feasibility of the study dose and route of administration, as well as to provide preliminary data on efficacy in reduction of depressive and suicidal symptoms as well as length of stay. Select patients will be given 0.2mg/kg of ketamine IV and observed in the ED for two hours. Vital signs and symptoms will be monitored. Patients will then be transferred to an admitting psychiatric hospital for definitive care as per standard of care. Surveys will be administered at times 0, 2 hours, 24 hours, and 72 hours to assess depressive and suicidal symptoms. ED providers and nursing staff will be asked to complete a short survey assessing ease of use and feasibility for ED administration for this purpose.

Specific aims are as follows:

  1. To determine the safety of ketamine as a single IV dose in the ED for acutely suicidal patients.
  2. To determine the feasibility of ketamine administration in the ED for the acutely suicidal patient.
  3. To determine the impact of ketamine administration on depression and suicidal ideation in the acute phase as measured by the MADRS and C-SSRS.
  4. To determine the impact on hospital length of stay calculated from ED arrival until discharge from admitting psychiatric hospital.
03

Conditions studied

  • Suicide
  • Suicidal Ideation
  • Depression

Browse trials for

04

In context

Suicidal Ideation Reclassified

570 studies on the registry are indexed under Suicidal Ideation; 204 are open to participants now.

This study's planned enrollment of 50 is below the median of 80 across 470 interventional studies indexed under Suicidal Ideation.

Browse Suicidal Ideation studies →

Lead sponsor

This is the only study on the registry with Lindsay Maguire, MD as lead sponsor.

Compared within Suicidal Ideation, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Suicide. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acutely Suicidality ("yes" answer to any of items 4 or 5 on C-SSRS "Suicidal Ideation" category)
  • Require inpatient stabilization for SI or actions based on clinical observation and interview
  • Are accepted for psychiatric stabilization at the University of Kansas Medical Center's Strawberry Hill campus
  • Have a Glasgow Coma Score (GCS) of 15
  • Age 18-65

Exclusion criteria

Exclusion Criteria:

  • Current or past history of psychosis
  • Current or recent (past 4 weeks) symptoms of mania/hypomania as defined by Young Mania Rating Scale (YRMS) score of 12 or greater
  • History of ketamine use disorder
  • History of liver transplant
  • Pregnancy or breastfeeding
  • Imprisonment or inability to consent
  • Positive urine drug screen or serum alcohol level
  • Hypertension (SBP > 160 or DBP > 100 before administration of ketamine)
  • Hypotension (SBP \< 90)
  • Presence of acute medical condition requiring admission to medical service
  • Allergy, intolerance, or previous adverse reaction to ketamine
  • Patient has 8+ lifetime ketamine exposures
  • The treating physician determines that the patient is not a good candidate for the study (e.g. medical condition/procedure, medication that would contradindicate ketamine treatment)
06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Ketamine

    All patients will receive the experimental drug.

    Drug: Ketamine

Interventions

  • Patients will receive 0.2mg/kg of IV ketamine

07

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Safety of use of ketamine for SI in the ED, as assessed by number and severity of reported serious adverse outcomes.

    Time frame: 2 hours

  2. Provider and Nursing Attitudes toward use of Ketamine for Suicidal Patients in the ED [Feasibility]

    A questionnaire will be given to providers and nursing staff to assess \[1\] perceived safety, \[2\] provider comfort, \[3\] perceived efficacy, and \[4\] perceived feasibility for ED use as rated on a Likert scale from 1-5, with 5 relaying best perceived outcomes.

    Time frame: 2 hours

Secondary outcomes

  1. Change in Suicidal Ideation

    Change of SI in ED patients after ketamine administration, as measured by the Columbia Suicide Severity Rating Scale (ideation subscore range 1-5, with higher number indicating increasing suicidal ideation; intensity subscore rating 2-25, with higher number indicating greater severity of suicidal ideation) and Montgomery-Asberg Depression Rating Scale.

    Time frame: 72 hours

  2. Hospital Length of Stay

    Impact of administration of ketamine on overall psychiatric hospital length of stay.

    Time frame: up to 2 weeks

08

Study locations

1 of 2 sites recruiting
  • University of Kansas Strawberry Hill Campus
    Kansas City, Kansas 66101, United States
    Not yet recruiting
  • University of Kansas Medical Center Emergency Department
    Kansas City, Kansas 66160, United States
    Recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Apr 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 17, 2023
StartActual
May 1, 2024
Primary completionEst.
Apr 2026
CompletionEst.
Apr 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06085937
Lead sponsor
Lindsay Maguire, MD
Responsible party
Lindsay Maguire, MD (Assistant Professor of Emergency Medicine, University of Kansas Medical Center) — Sponsor-investigator
First posted
Oct 17, 2023
Start date
May 1, 2024
Primary completion
Apr 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Lindsay Maguire, MD
Contact
lmaguire@kumc.edu
913-588-3580
Lucas Lemar
Contact
llemar@kumc.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion